Early cytomegalovirus infections following allogeneic stem cell transplantation: a comparison between non-malignant and malignant haematological disorders.

Abstract

The haematological indications for allogeneic stem cell transplantation can be broadly divided into non-malignant and malignant disorders. We compared the incidence and risk factors for post-transplant cytomegalovirus (CMV) infections between these two biologically diverse subgroups of haematological conditions. Out of 105 allogeneic transplants, 64 and 41 were for underlying non-malignant and malignant indications respectively. CMV infections were significantly more frequent (P=0.016) in the malignant subgroup. Pre-transplant recipient CMV seropositivity in both subgroups (negative versus positive; non-malignant,P=0.023; malignant, p<0.001), donor seropositivity (P=0.002) and acute graft-versus-host disease (GVHD) (P=0.02) in the non-malignant subgroup and > or =3 courses of previous cytotoxic therapy (P=0.023) in the malignant subgroup were found to be associated with an increased risk of CMV infections. On multivariate analysis, donor seropositivity in the non-malignant patients (negative versus positive,P=0.022; odds ratio: 0.18) and recipient seropositivity in patients with malignancies (negative versus positive; P=0.001, odds ratio: 0.01) were identified to be significant factors for risk of CMV infection.

• Authors: Md Serajul Islam, Parameswaran Anoop, Phil Rice, Reuben Benjamin, Preeti Datta-Nemdharry, Edward C Gordon-Smith, Judith C W Marsh
• Journal: Hematology (Amsterdam, Netherlands) (Hematology) Vol. 15 Issue 1 Pg. 4-10 (Feb 2010) ISSN: 1607-8454 [Electronic] England
• PMID: 20132656 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Immunosuppressive Agents

Topics

• Adolescent
• Adult
• Bone Marrow Transplantation (adverse effects)
• Cord Blood Stem Cell Transplantation
• Cytomegalovirus Infections (epidemiology, transmission)
• Disease Susceptibility
• Female
• Graft vs Host Disease (drug therapy, epidemiology)
• Hematologic Diseases (complications, surgery)
• Hematologic Neoplasms (complications, surgery)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Immunocompromised Host
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Incidence
• Living Donors
• Male
• Middle Aged
• Opportunistic Infections (epidemiology)
• Peripheral Blood Stem Cell Transplantation (adverse effects)
• Postoperative Complications (epidemiology)
• Prospective Studies
• Reoperation
• Risk Factors
• Transplantation, Homologous (adverse effects)
• Virus Activation
• Young Adult